Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
25
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Atkinson Edward Morrow III | Director | 14 | $0 | $247.9K | 2025-10-30 |
| Le-Nguyen Quoc | See Remarks | 74 | $0 | $880.3K | 2025-10-30 |
| DiRocco Derek | Director | 14 | $0 | $0 | 2025-10-30 |
| Martins Ryan | Chief Financial Officer | 65 | $0 | $638.8K | 2025-10-30 |
| Shah Rajeev M. | Director, 10% Owner | 13 | $27.63M | $0 | 2025-10-30 |
| McWherter Charles | Director | 8 | $179.8K | $0 | 2025-10-30 |
| Altschuler Steven | Director | 14 | $0 | $0 | 2025-10-30 |
| Babler Martin | Director | 4 | $0 | $0 | 2025-10-30 |
| Sarena Francis Willard | Chief Operating Officer | 9 | $0 | $0 | 2025-10-30 |
| PALEKAR ROHAN | Chief Executive Officer | 61 | $293.6K | $1.72M | 2025-10-30 |
| Hayden Michael R | Director | 33 | $1.38M | $0 | 2025-10-30 |
| Mansbach Harry H | Chief Medical Officer | 51 | $0 | $0 | 2025-10-30 |
| Zoth Lota S. | Director | 12 | $0 | $0 | 2025-10-30 |
| LAPORTE KATHLEEN | Director | 13 | $0 | $235.0K | 2025-10-30 |
| RA Capital Healthcare Fund LP | Director, 10% Owner | 9 | $38.27M | $0 | 2025-02-03 |
| Kolchinsky Peter | Director, 10% Owner | 8 | $78.28M | $0 | 2025-01-30 |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | 2 | $76.40M | $0 | 2023-03-24 |
| Grunberg Gregory | Director, 10% Owner | 12 | $12.20M | $23.5K | 2023-02-09 |
| RA Capital Nexus Fund, L.P. | Director, 10% Owner | 3 | $18.97M | $0 | 2022-10-18 |
| Waisbourd Ram | See Remarks | 53 | $0 | $2.06M | 2022-02-17 |
| OrbiMed Advisors Israel II Ltd | Director, 10% Owner | 10 | $13.40M | $592.4K | 2022-01-26 |
| Naschitz Anat | Director, 10% Owner | 11 | $13.40M | $7.70M | 2021-04-15 |
| Longitude Venture Partners III, L.P. | 10% Owner | 8 | $12.20M | $0 | 2020-11-16 |
| OrbiMed Capital GP VI LLC | Director, 10% Owner | 2 | $0 | $7.70M | 2020-09-21 |
| Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | 3 | $4.00M | $0 | 2019-11-13 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Mansbach Harry H | Chief Medical Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 45,000 | — | $0 | 0 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 70,000 | — | $0 | 0 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 195,000 | — | $0 | 0 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 320,000 | — | $0 | 0 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 120,000 | — | $0 | 0 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 67,500 | — | $0 | 0 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 98,204 | — | $0 | 0 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 39,037 | — | $0 | 0 | SEC↗ |
| Sarena Francis Willard | Chief Operating Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 215,000 | — | $0 | 0 | SEC↗ |
| Sarena Francis Willard | Chief Operating Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 350,000 | — | $0 | 0 | SEC↗ |
| DiRocco Derek | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 7,000 | — | $0 | 0 | SEC↗ |
| DiRocco Derek | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 7,000 | — | $0 | 0 | SEC↗ |
| DiRocco Derek | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 12,500 | — | $0 | 0 | SEC↗ |
| DiRocco Derek | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 25,000 | — | $0 | 0 | SEC↗ |
| DiRocco Derek | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 27,400 | — | $0 | 0 | SEC↗ |
| DiRocco Derek | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 45,150 | — | $0 | 0 | SEC↗ |
| DiRocco Derek | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 56,400 | — | $0 | 0 | SEC↗ |
| Babler Martin | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 56,400 | — | $0 | 0 | SEC↗ |
| Babler Martin | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 67,700 | — | $0 | 0 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | D To issuer deriv | 2025-10-30 | 2025-10-30 | 195,000 | — | $0 | 0 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | D To issuer deriv | 2025-10-30 | 2025-10-30 | 50,000 | — | $0 | 0 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | D To issuer deriv | 2025-10-30 | 2025-10-30 | 67,500 | — | $0 | 0 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | D To issuer deriv | 2025-10-30 | 2025-10-30 | 70,000 | — | $0 | 0 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | D To issuer deriv | 2025-10-30 | 2025-10-30 | 120,000 | — | $0 | 0 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | D To issuer deriv | 2025-10-30 | 2025-10-30 | 3,312 | — | $0 | 0 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | D To issuer deriv | 2025-10-30 | 2025-10-30 | 320,000 | — | $0 | 0 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | D To issuer deriv | 2025-10-30 | 2025-10-30 | 26,400 | — | $0 | 0 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | D To issuer deriv | 2025-10-30 | 2025-10-30 | 17,500 | — | $0 | 0 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | D To issuer deriv | 2025-10-30 | 2025-10-30 | 4,063 | — | $0 | 0 | SEC↗ |
| Zoth Lota S. | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 56,400 | — | $0 | 0 | SEC↗ |
| Zoth Lota S. | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 45,150 | — | $0 | 0 | SEC↗ |
| Zoth Lota S. | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 27,400 | — | $0 | 0 | SEC↗ |
| Zoth Lota S. | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 25,000 | — | $0 | 0 | SEC↗ |
| Zoth Lota S. | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 12,500 | — | $0 | 0 | SEC↗ |
| Zoth Lota S. | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 20,000 | — | $0 | 0 | SEC↗ |
| Atkinson Edward Morrow III | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 56,400 | — | $0 | 0 | SEC↗ |
| Atkinson Edward Morrow III | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 45,150 | — | $0 | 0 | SEC↗ |
| Atkinson Edward Morrow III | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 27,400 | — | $0 | 0 | SEC↗ |
| Atkinson Edward Morrow III | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 20,000 | — | $0 | 0 | SEC↗ |
| McWherter Charles | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 67,700 | — | $0 | 0 | SEC↗ |
| McWherter Charles | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 56,400 | — | $0 | 0 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 170,000 | — | $0 | 0 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 203,750 | — | $0 | 0 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 220,000 | — | $0 | 0 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 120,231 | — | $0 | 0 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 132,242 | — | $0 | 0 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 848,000 | — | $0 | 0 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 605,000 | — | $0 | 0 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 300,000 | — | $0 | 0 | SEC↗ |
| Altschuler Steven | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 56,400 | — | $0 | 0 | SEC↗ |
| Altschuler Steven | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 12,500 | — | $0 | 0 | SEC↗ |
| Altschuler Steven | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 25,000 | — | $0 | 0 | SEC↗ |
| Altschuler Steven | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 45,150 | — | $0 | 0 | SEC↗ |
| Altschuler Steven | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 27,400 | — | $0 | 0 | SEC↗ |
| Altschuler Steven | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 40,000 | — | $0 | 0 | SEC↗ |
| Altschuler Steven | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 7,000 | — | $0 | 0 | SEC↗ |
| Martins Ryan | Chief Financial Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 47,500 | — | $0 | 0 | SEC↗ |
| Martins Ryan | Chief Financial Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 57,500 | — | $0 | 0 | SEC↗ |
| Martins Ryan | Chief Financial Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 48,102 | — | $0 | 0 | SEC↗ |
| Martins Ryan | Chief Financial Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 110,000 | — | $0 | 0 | SEC↗ |
| Martins Ryan | Chief Financial Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 175,000 | — | $0 | 0 | SEC↗ |
| Martins Ryan | Chief Financial Officer | D To issuer deriv | 2025-10-30 | 2025-10-30 | 300,000 | — | $0 | 0 | SEC↗ |
| Hayden Michael R | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 45,150 | — | $0 | 0 | SEC↗ |
| Hayden Michael R | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 22,730 | — | $0 | 0 | SEC↗ |
| Hayden Michael R | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 2,933 | — | $0 | 0 | SEC↗ |
| Hayden Michael R | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 7,000 | — | $0 | 0 | SEC↗ |
| Hayden Michael R | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 7,000 | — | $0 | 0 | SEC↗ |
| Hayden Michael R | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 12,500 | — | $0 | 0 | SEC↗ |
| Hayden Michael R | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 25,000 | — | $0 | 0 | SEC↗ |
| Hayden Michael R | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 27,400 | — | $0 | 0 | SEC↗ |
| Hayden Michael R | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 56,400 | — | $0 | 0 | SEC↗ |
| Hayden Michael R | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 27,647 | — | $0 | 0 | SEC↗ |
| LAPORTE KATHLEEN | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 56,400 | — | $0 | 0 | SEC↗ |
| LAPORTE KATHLEEN | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 45,150 | — | $0 | 0 | SEC↗ |
| LAPORTE KATHLEEN | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 25,000 | — | $0 | 0 | SEC↗ |
| LAPORTE KATHLEEN | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 12,500 | — | $0 | 0 | SEC↗ |
| LAPORTE KATHLEEN | Director | D To issuer deriv | 2025-10-30 | 2025-10-30 | 27,400 | — | $0 | 0 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | D To issuer deriv | 2025-10-30 | 2025-11-03 | 12,500 | — | $0 | 0 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | D To issuer deriv | 2025-10-30 | 2025-11-03 | 45,150 | — | $0 | 0 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | D To issuer deriv | 2025-10-30 | 2025-11-03 | 27,400 | — | $0 | 0 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | D To issuer deriv | 2025-10-30 | 2025-11-03 | 25,000 | — | $0 | 0 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | D To issuer deriv | 2025-10-30 | 2025-11-03 | 56,400 | — | $0 | 0 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | D To issuer deriv | 2025-10-30 | 2025-11-03 | 7,000 | — | $0 | 0 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | D To issuer deriv | 2025-10-30 | 2025-11-03 | 7,000 | — | $0 | 0 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | D To issuer deriv | 2025-10-30 | 2025-11-03 | 4,331,081 | — | $0 | 0 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | A Award | 2025-10-30 | 2025-10-30 | 50,000 | — | $0 | 352,656 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | U Tender | 2025-10-30 | 2025-10-30 | 352,656 | — | $0 | 0 | SEC↗ |
| Sarena Francis Willard | Chief Operating Officer | U Tender | 2025-10-30 | 2025-10-30 | 75,310 | — | $0 | 0 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | U Tender | 2025-10-30 | 2025-10-30 | 13,694 | — | $0 | 0 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | U Tender | 2025-10-30 | 2025-10-30 | 351,684 | — | $0 | 0 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award | 2025-10-30 | 2025-10-30 | 50,000 | — | $0 | 351,684 | SEC↗ |
| McWherter Charles | Director | U Tender | 2025-10-30 | 2025-10-30 | 25,000 | — | $0 | 0 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | A Award | 2025-10-30 | 2025-10-30 | 125,000 | — | $0 | 934,273 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | U Tender | 2025-10-30 | 2025-10-30 | 934,273 | — | $0 | 0 | SEC↗ |
| Martins Ryan | Chief Financial Officer | A Award | 2025-10-30 | 2025-10-30 | 35,000 | — | $0 | 374,295 | SEC↗ |
| Martins Ryan | Chief Financial Officer | U Tender | 2025-10-30 | 2025-10-30 | 374,295 | — | $0 | 0 | SEC↗ |
| Hayden Michael R | Director | U Tender | 2025-10-30 | 2025-10-30 | 103,978 | — | $0 | 0 | SEC↗ |
| Hayden Michael R | Director | U Tender | 2025-10-30 | 2025-10-30 | 61,538 | — | $0 | 0 | SEC↗ |
| Hayden Michael R | Director | U Tender | 2025-10-30 | 2025-10-30 | 80,904 | — | $0 | 0 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | D To issuer | 2025-10-30 | 2025-11-03 | 335,364 | — | $0 | 0 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | D To issuer | 2025-10-30 | 2025-11-03 | 19,554,319 | — | $0 | 0 | SEC↗ |
| Martins Ryan | Chief Financial Officer | M Exercise deriv | 2025-10-22 | 2025-10-23 | 3,898 | — | $0 | 48,102 | SEC↗ |
| Martins Ryan | Chief Financial Officer | M Exercise deriv | 2025-10-22 | 2025-10-23 | 76,901 | — | $0 | 0 | SEC↗ |
| Martins Ryan | Chief Financial Officer | M Exercise | 2025-10-22 | 2025-10-23 | 76,901 | $3.11 | $239.2K | 335,397 | SEC↗ |
| Martins Ryan | Chief Financial Officer | M Exercise | 2025-10-22 | 2025-10-23 | 3,898 | $4.44 | $17.3K | 339,295 | SEC↗ |
| Sarena Francis Willard | Chief Operating Officer | F Tax w/h | 2025-08-05 | 2025-08-05 | 2,979 | $9.69 | $28.9K | 74,231 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | F Tax w/h | 2025-08-01 | 2025-08-05 | 55,836 | $9.16 | $511.5K | 808,070 | SEC↗ |
| Sarena Francis Willard | Chief Operating Officer | F Tax w/h | 2025-08-01 | 2025-08-05 | 3,206 | $9.16 | $29.4K | 77,210 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2025-08-01 | 2025-08-05 | 7,680 | $9.16 | $70.3K | 253,496 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2025-08-01 | 2025-08-05 | 7,680 | $9.16 | $70.3K | 302,656 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2025-08-01 | 2025-08-05 | 7,680 | $9.16 | $70.3K | 301,684 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2025-08-01 | 2025-08-05 | 522 | $9.16 | $4.8K | 13,694 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | S Sale | 2025-07-15 | 2025-07-17 | 10,461 | $11.02 | $115.3K | 309,364 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2025-06-12 | 2025-06-13 | 8,498 | $9.62 | $81.8K | 319,825 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2025-06-12 | 2025-06-13 | 534 | $9.62 | $5.1K | 14,216 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2025-06-12 | 2025-06-13 | 8,498 | $9.62 | $81.8K | 310,336 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2025-06-12 | 2025-06-13 | 8,498 | $9.62 | $81.8K | 261,176 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | S Sale | 2025-04-15 | 2025-04-17 | 15,329 | $5.95 | $91.2K | 328,323 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2025-02-17 | 2025-02-19 | 780 | $10.57 | $8.2K | 269,674 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2025-02-17 | 2025-02-19 | 1,050 | $10.57 | $11.1K | 318,834 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | F Tax w/h | 2025-02-17 | 2025-02-19 | 3,249 | $10.57 | $34.3K | 862,240 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2025-02-17 | 2025-02-19 | 1,050 | $10.57 | $11.1K | 343,652 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2025-02-09 | 2025-02-11 | 3,817 | $11.41 | $43.6K | 319,884 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2025-02-09 | 2025-02-11 | 3,828 | $11.41 | $43.7K | 270,454 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2025-02-09 | 2025-02-11 | 3,793 | $11.41 | $43.3K | 344,702 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | F Tax w/h | 2025-02-09 | 2025-02-11 | 8,946 | $11.41 | $102.1K | 864,692 | SEC↗ |
| McWherter Charles | Director | A Award deriv | 2025-02-03 | 2025-02-05 | 56,400 | — | $0 | 56,400 | SEC↗ |
| Hayden Michael R | Director | A Award deriv | 2025-02-03 | 2025-02-05 | 56,400 | — | $0 | 56,400 | SEC↗ |
| Altschuler Steven | Director | A Award deriv | 2025-02-03 | 2025-02-05 | 56,400 | — | $0 | 56,400 | SEC↗ |
| Zoth Lota S. | Director | A Award deriv | 2025-02-03 | 2025-02-05 | 56,400 | — | $0 | 56,400 | SEC↗ |
| Babler Martin | Director | A Award deriv | 2025-02-03 | 2025-02-05 | 56,400 | — | $0 | 56,400 | SEC↗ |
| DiRocco Derek | Director | A Award deriv | 2025-02-03 | 2025-02-05 | 56,400 | — | $0 | 56,400 | SEC↗ |
| Atkinson Edward Morrow III | Director | A Award deriv | 2025-02-03 | 2025-02-05 | 56,400 | — | $0 | 56,400 | SEC↗ |
| LAPORTE KATHLEEN | Director | A Award deriv | 2025-02-03 | 2025-02-05 | 56,400 | — | $0 | 56,400 | SEC↗ |
| RA Capital Healthcare Fund LP | Director, 10% Owner | A Award deriv | 2025-02-03 | 2025-02-05 | 56,400 | — | $0 | 56,400 | SEC↗ |
| Sarena Francis Willard | Chief Operating Officer | A Award deriv | 2025-02-01 | 2025-02-04 | 215,000 | — | $0 | 215,000 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | A Award deriv | 2025-02-01 | 2025-02-04 | 320,000 | — | $0 | 320,000 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | A Award deriv | 2025-02-01 | 2025-02-04 | 848,000 | — | $0 | 848,000 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award deriv | 2025-02-01 | 2025-02-04 | 320,000 | — | $0 | 320,000 | SEC↗ |
| Martins Ryan | Chief Financial Officer | A Award deriv | 2025-02-01 | 2025-02-04 | 300,000 | — | $0 | 300,000 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award deriv | 2025-02-01 | 2025-02-19 | 17,500 | — | $0 | 17,500 | SEC↗ |
| Sarena Francis Willard | Chief Operating Officer | A Award | 2025-02-01 | 2025-02-04 | 53,750 | — | $0 | 78,750 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2025-02-01 | 2025-02-04 | 3,338 | $9.60 | $32.0K | 323,701 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | A Award | 2025-02-01 | 2025-02-04 | 80,000 | — | $0 | 327,039 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | A Award | 2025-02-01 | 2025-02-04 | 200,000 | — | $0 | 883,236 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | F Tax w/h | 2025-02-01 | 2025-02-04 | 9,598 | $9.60 | $92.1K | 873,638 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | A Award | 2025-02-01 | 2025-02-04 | 212,000 | — | $0 | 683,236 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award | 2025-02-01 | 2025-02-04 | 80,000 | — | $0 | 351,833 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2025-02-01 | 2025-02-04 | 3,338 | $9.60 | $32.0K | 348,495 | SEC↗ |
| Martins Ryan | Chief Financial Officer | A Award | 2025-02-01 | 2025-02-04 | 80,000 | — | $0 | 277,620 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2025-02-01 | 2025-02-04 | 3,338 | $9.60 | $32.0K | 274,282 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award | 2025-02-01 | 2025-02-19 | 8,750 | $9.60 | $84.0K | 14,750 | SEC↗ |
| Kolchinsky Peter | Director, 10% Owner | P Buy | 2025-01-30 | 2025-02-03 | 5,714,285 | $8.75 | $50.00M | 19,554,319 | SEC↗ |
| McWherter Charles | Director | P Buy | 2025-01-22 | 2025-01-23 | 10,000 | $6.71 | $67.1K | 25,000 | SEC↗ |
| McWherter Charles | Director | P Buy | 2025-01-21 | 2025-01-23 | 5,000 | $6.55 | $32.8K | 15,000 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | S Sale | 2025-01-15 | 2025-01-17 | 10,963 | $6.49 | $71.1K | 271,833 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award | 2024-12-12 | 2025-02-19 | 6,000 | — | $0 | 6,000 | SEC↗ |
| Martins Ryan | Chief Financial Officer | A Award | 2024-12-12 | 2024-12-16 | 95,000 | — | $0 | 197,620 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award | 2024-12-12 | 2024-12-16 | 95,000 | — | $0 | 282,796 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | A Award | 2024-12-12 | 2024-12-16 | 95,000 | — | $0 | 247,039 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | P Buy | 2024-12-06 | 2024-12-10 | 5,000 | $7.89 | $39.5K | 471,236 | SEC↗ |
| McWherter Charles | Director | P Buy | 2024-12-05 | 2024-12-09 | 10,000 | $8.00 | $80.0K | 10,000 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | P Buy | 2024-11-22 | 2024-11-25 | 10,000 | $8.35 | $83.5K | 466,236 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | P Buy deriv | 2024-11-14 | 2024-11-18 | 3,250,000 | $8.50 | $27.63M | 4,331,081 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | S Sale | 2024-10-30 | 2024-11-01 | 27,955 | $8.12 | $227.0K | 187,796 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2024-09-09 | 2024-09-10 | 5,352 | $8.46 | $45.3K | 215,751 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2024-09-09 | 2024-09-10 | 3,212 | $8.46 | $27.2K | 102,620 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2024-09-09 | 2024-09-10 | 5,352 | $8.46 | $45.3K | 152,039 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2024-08-17 | 2024-08-19 | 1,046 | $8.04 | $8.4K | 221,103 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2024-08-17 | 2024-08-19 | 777 | $8.04 | $6.2K | 105,832 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | F Tax w/h | 2024-08-17 | 2024-08-19 | 4,601 | $8.04 | $37.0K | 456,236 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2024-08-17 | 2024-08-19 | 1,046 | $8.04 | $8.4K | 157,391 | SEC↗ |
| Sarena Francis Willard | Chief Operating Officer | A Award deriv | 2024-08-05 | 2024-08-07 | 350,000 | — | $0 | 350,000 | SEC↗ |
| McWherter Charles | Director | A Award deriv | 2024-08-05 | 2024-08-07 | 67,700 | — | $0 | 67,700 | SEC↗ |
| Sarena Francis Willard | Chief Operating Officer | A Award | 2024-08-05 | 2024-08-07 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Babler Martin | Director | A Award deriv | 2024-05-02 | 2024-05-03 | 67,700 | — | $0 | 67,700 | SEC↗ |
| Kolchinsky Peter | Director, 10% Owner | X Exercise deriv | 2024-04-11 | 2024-04-15 | 2,816,900 | — | $0 | 0 | SEC↗ |
| Kolchinsky Peter | Director, 10% Owner | X Exercise | 2024-04-11 | 2024-04-15 | 1,408,450 | $5.33 | $7.51M | 13,840,034 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award deriv | 2024-04-02 | 2025-02-19 | 26,400 | — | $0 | 26,400 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | M Exercise deriv | 2024-04-01 | 2024-04-03 | 25,000 | — | $0 | 120,231 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | M Exercise | 2024-04-01 | 2024-04-03 | 25,000 | $1.93 | $48.3K | 511,889 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | S Sale | 2024-04-01 | 2024-04-03 | 52,718 | $10.91 | $575.2K | 459,171 | SEC↗ |
| Kolchinsky Peter | Director, 10% Owner | P Buy | 2024-03-04 | 2024-03-06 | 1,350,000 | $15.35 | $20.72M | 12,431,584 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | S Sale | 2024-02-26 | 2024-02-28 | 4,477 | $10.76 | $48.2K | 486,889 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2024-02-17 | 2024-02-23 | 1,046 | $9.74 | $10.2K | 158,437 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2024-02-17 | 2024-02-23 | 1,046 | $9.74 | $10.2K | 222,149 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | F Tax w/h | 2024-02-17 | 2024-02-23 | 4,602 | $9.74 | $44.8K | 491,366 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2024-02-17 | 2024-02-23 | 778 | $9.74 | $7.6K | 106,609 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | F Tax w/h | 2024-02-09 | 2024-02-13 | 12,670 | $8.45 | $107.1K | 480,968 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2024-02-09 | 2024-02-13 | 3,568 | $8.45 | $30.1K | 223,195 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2024-02-09 | 2024-02-13 | 3,568 | $8.45 | $30.1K | 159,483 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2024-02-09 | 2024-02-13 | 3,568 | $8.45 | $30.1K | 107,387 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2024-02-05 | 2024-02-05 | 892 | $9.80 | $8.7K | 110,955 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | F Tax w/h | 2024-02-05 | 2024-02-05 | 5,068 | $9.80 | $49.7K | 493,646 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2024-02-05 | 2024-02-05 | 1,190 | $9.80 | $11.7K | 226,763 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2024-02-05 | 2024-02-05 | 1,190 | $9.80 | $11.7K | 163,051 | SEC↗ |
| Kolchinsky Peter | Director, 10% Owner | A Award deriv | 2024-02-01 | 2024-04-15 | 45,150 | — | $0 | 45,150 | SEC↗ |
| Martins Ryan | Chief Financial Officer | A Award deriv | 2024-02-01 | 2024-02-05 | 175,000 | — | $0 | 175,000 | SEC↗ |
| Zoth Lota S. | Director | A Award deriv | 2024-02-01 | 2024-02-05 | 45,150 | — | $0 | 45,150 | SEC↗ |
| Altschuler Steven | Director | A Award deriv | 2024-02-01 | 2024-02-05 | 45,150 | — | $0 | 45,150 | SEC↗ |
| LAPORTE KATHLEEN | Director | A Award deriv | 2024-02-01 | 2024-02-05 | 45,150 | — | $0 | 45,150 | SEC↗ |
| Atkinson Edward Morrow III | Director | A Award deriv | 2024-02-01 | 2024-02-05 | 45,150 | — | $0 | 45,150 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | A Award deriv | 2024-02-01 | 2024-02-05 | 605,000 | — | $0 | 605,000 | SEC↗ |
| DiRocco Derek | Director | A Award deriv | 2024-02-01 | 2024-02-05 | 45,150 | — | $0 | 45,150 | SEC↗ |
| Hayden Michael R | Director | A Award deriv | 2024-02-01 | 2024-02-05 | 45,150 | — | $0 | 45,150 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award deriv | 2024-02-01 | 2024-02-05 | 195,000 | — | $0 | 195,000 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | A Award deriv | 2024-02-01 | 2024-02-05 | 195,000 | — | $0 | 195,000 | SEC↗ |
| Martins Ryan | Chief Financial Officer | A Award | 2024-02-01 | 2024-02-05 | 48,750 | — | $0 | 111,847 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | A Award | 2024-02-01 | 2024-02-05 | 150,000 | — | $0 | 498,714 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award | 2024-02-01 | 2024-02-05 | 48,750 | — | $0 | 227,953 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | A Award | 2024-02-01 | 2024-02-05 | 48,750 | — | $0 | 164,241 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | A Award | 2024-01-05 | 2024-01-08 | 75,000 | — | $0 | 376,225 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | F Tax w/h | 2024-01-05 | 2024-01-08 | 27,511 | $11.53 | $317.2K | 348,714 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award | 2024-01-05 | 2024-01-08 | 25,000 | — | $0 | 188,874 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2024-01-05 | 2024-01-08 | 9,671 | $11.53 | $111.5K | 179,203 | SEC↗ |
| Martins Ryan | Chief Financial Officer | A Award | 2024-01-05 | 2024-01-08 | 15,000 | — | $0 | 69,221 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2024-01-05 | 2024-01-08 | 6,124 | $11.53 | $70.6K | 63,097 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | A Award | 2024-01-05 | 2024-01-08 | 25,000 | — | $0 | 125,162 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2024-01-05 | 2024-01-08 | 9,671 | $11.53 | $111.5K | 115,491 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | M Exercise deriv | 2023-12-29 | 2024-01-03 | 50,000 | — | $0 | 145,231 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | M Exercise | 2023-12-29 | 2024-01-03 | 50,000 | $1.93 | $96.5K | 351,225 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | S Sale | 2023-12-29 | 2024-01-03 | 50,000 | $11.20 | $560.0K | 301,225 | SEC↗ |
| RA Capital Healthcare Fund LP | Director, 10% Owner | P Buy deriv | 2023-12-11 | 2023-12-13 | 1,081,081 | $9.25 | $10.00M | 1,081,081 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2023-09-09 | 2023-09-12 | 4,958 | $16.61 | $82.4K | 163,874 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2023-09-09 | 2023-09-12 | 2,074 | $16.61 | $34.4K | 54,221 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2023-09-09 | 2023-09-12 | 3,821 | $16.61 | $63.5K | 100,162 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2023-08-17 | 2023-08-21 | 753 | $15.46 | $11.6K | 56,295 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | F Tax w/h | 2023-08-17 | 2023-08-21 | 4,501 | $15.46 | $69.6K | 300,950 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2023-08-17 | 2023-08-21 | 1,014 | $15.46 | $15.7K | 103,983 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2023-08-01 | 2023-08-21 | 1,014 | $15.46 | $15.7K | 168,832 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2023-08-01 | 2023-08-21 | 577 | $15.64 | $9.0K | 169,846 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2023-08-01 | 2023-08-21 | 346 | $15.64 | $5.4K | 57,048 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2023-08-01 | 2023-08-21 | 577 | $15.64 | $9.0K | 104,997 | SEC↗ |
| LAPORTE KATHLEEN | Director | M Exercise deriv | 2023-07-17 | 2023-07-18 | 12,500 | — | $0 | 12,500 | SEC↗ |
| LAPORTE KATHLEEN | Director | S Sale | 2023-07-17 | 2023-07-18 | 12,500 | $18.80 | $235.0K | 0 | SEC↗ |
| LAPORTE KATHLEEN | Director | M Exercise | 2023-07-17 | 2023-07-18 | 12,500 | $2.64 | $33.0K | 12,500 | SEC↗ |
| Martins Ryan | Chief Financial Officer | A Award | 2023-06-30 | 2023-07-05 | 5,834 | — | $0 | 59,412 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2023-06-30 | 2023-07-05 | 2,018 | $18.95 | $38.2K | 57,394 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | A Award | 2023-06-30 | 2023-07-05 | 33,334 | — | $0 | 321,978 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | F Tax w/h | 2023-06-30 | 2023-07-05 | 16,527 | $18.95 | $313.2K | 305,451 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award | 2023-06-30 | 2023-07-05 | 8,334 | — | $0 | 173,305 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2023-06-30 | 2023-07-05 | 2,882 | $18.95 | $54.6K | 170,423 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | A Award | 2023-06-30 | 2023-07-05 | 8,334 | — | $0 | 108,456 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2023-06-30 | 2023-07-05 | 2,882 | $18.95 | $54.6K | 105,574 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | M Exercise deriv | 2023-06-05 | 2023-06-07 | 15,000 | — | $0 | 195,231 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | S Sale | 2023-06-05 | 2023-06-07 | 15,000 | $20.00 | $300.0K | 286,978 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | M Exercise | 2023-06-05 | 2023-06-07 | 15,000 | $1.93 | $28.9K | 301,978 | SEC↗ |
| Atkinson Edward Morrow III | Director | M Exercise deriv | 2023-06-01 | 2023-06-05 | 6,250 | — | $0 | 0 | SEC↗ |
| Atkinson Edward Morrow III | Director | S Sale | 2023-06-01 | 2023-06-05 | 6,250 | $17.91 | $111.9K | 0 | SEC↗ |
| Atkinson Edward Morrow III | Director | M Exercise | 2023-06-01 | 2023-06-05 | 6,250 | $2.61 | $16.3K | 6,250 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | M Exercise deriv | 2023-05-09 | 2023-05-11 | 60,945 | — | $0 | 4,063 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | M Exercise deriv | 2023-05-09 | 2023-05-11 | 18,626 | — | $0 | 3,312 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | S Sale | 2023-05-09 | 2023-05-11 | 13,683 | $18.11 | $247.8K | 164,971 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | M Exercise | 2023-05-09 | 2023-05-11 | 18,626 | $3.11 | $57.9K | 178,654 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | M Exercise | 2023-05-09 | 2023-05-11 | 60,945 | $3.11 | $189.5K | 160,028 | SEC↗ |
| Martins Ryan | Chief Financial Officer | S Sale | 2023-04-04 | 2023-04-06 | 8,721 | $14.95 | $130.4K | 53,578 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | A Award | 2023-03-31 | 2023-04-04 | 8,333 | — | $0 | 103,004 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2023-03-31 | 2023-04-04 | 2,882 | $15.23 | $43.9K | 100,122 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2023-03-31 | 2023-04-04 | 2,882 | $15.23 | $43.9K | 96,630 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2023-03-31 | 2023-04-04 | 1,297 | $15.23 | $19.8K | 99,083 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award | 2023-03-31 | 2023-04-04 | 3,750 | — | $0 | 100,380 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award | 2023-03-31 | 2023-04-04 | 8,333 | — | $0 | 99,512 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | A Award | 2023-03-31 | 2023-04-04 | 33,333 | — | $0 | 302,413 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | F Tax w/h | 2023-03-31 | 2023-04-04 | 15,443 | $15.23 | $235.2K | 286,970 | SEC↗ |
| Martins Ryan | Chief Financial Officer | A Award | 2023-03-31 | 2023-04-04 | 5,833 | — | $0 | 59,411 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2023-03-31 | 2023-04-04 | 2,018 | $15.23 | $30.7K | 57,393 | SEC↗ |
| Martins Ryan | Chief Financial Officer | A Award | 2023-03-31 | 2023-04-04 | 7,500 | — | $0 | 64,893 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2023-03-31 | 2023-04-04 | 2,594 | $15.23 | $39.5K | 62,299 | SEC↗ |
| Hayden Michael R | Director | P Buy | 2023-03-28 | 2023-03-30 | 61,538 | $16.15 | $993.8K | 61,538 | SEC↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | P Buy | 2023-03-24 | 2023-03-30 | 2,461,538 | $16.25 | $40.00M | 11,081,584 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | S Sale | 2023-03-23 | 2023-03-27 | 15,000 | $16.00 | $240.0K | 269,080 | SEC↗ |
| Martins Ryan | Chief Financial Officer | S Sale | 2023-03-23 | 2023-03-27 | 5,000 | $16.11 | $80.5K | 53,578 | SEC↗ |
| Atkinson Edward Morrow III | Director | M Exercise deriv | 2023-03-01 | 2023-03-03 | 10,000 | — | $0 | 20,000 | SEC↗ |
| Atkinson Edward Morrow III | Director | S Sale | 2023-03-01 | 2023-03-03 | 10,000 | $13.60 | $136.0K | 0 | SEC↗ |
| Atkinson Edward Morrow III | Director | M Exercise | 2023-03-01 | 2023-03-03 | 10,000 | $4.44 | $44.4K | 10,000 | SEC↗ |
| Martins Ryan | Chief Financial Officer | S Sale | 2023-02-21 | 2023-02-22 | 2,540 | $13.89 | $35.3K | 58,578 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | F Tax w/h | 2023-02-17 | 2023-02-22 | 6,279 | $13.97 | $87.7K | 284,072 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2023-02-17 | 2023-02-22 | 2,140 | $13.97 | $29.9K | 91,179 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2023-02-17 | 2023-02-22 | 1,750 | $13.97 | $24.4K | 61,118 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | F Tax w/h | 2023-02-17 | 2023-02-22 | 2,127 | $13.97 | $29.7K | 94,671 | SEC↗ |
| Kolchinsky Peter | Director, 10% Owner | A Award deriv | 2023-02-09 | 2024-04-15 | 27,400 | — | $0 | 27,400 | SEC↗ |
| DiRocco Derek | Director | A Award deriv | 2023-02-09 | 2023-02-13 | 27,400 | — | $0 | 27,400 | SEC↗ |
| Atkinson Edward Morrow III | Director | A Award deriv | 2023-02-09 | 2023-02-13 | 27,400 | — | $0 | 27,400 | SEC↗ |
| Hayden Michael R | Director | A Award deriv | 2023-02-09 | 2023-02-13 | 27,400 | — | $0 | 27,400 | SEC↗ |
| Grunberg Gregory | Director, 10% Owner | A Award deriv | 2023-02-09 | 2023-02-13 | 27,400 | — | $0 | 27,400 | SEC↗ |
| LAPORTE KATHLEEN | Director | A Award deriv | 2023-02-09 | 2023-02-13 | 27,400 | — | $0 | 27,400 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award deriv | 2023-02-09 | 2023-02-13 | 120,000 | — | $0 | 120,000 | SEC↗ |
| Zoth Lota S. | Director | A Award deriv | 2023-02-09 | 2023-02-13 | 27,400 | — | $0 | 27,400 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | A Award deriv | 2023-02-09 | 2023-02-13 | 300,000 | — | $0 | 300,000 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | A Award deriv | 2023-02-09 | 2023-02-13 | 120,000 | — | $0 | 120,000 | SEC↗ |
| Martins Ryan | Chief Financial Officer | A Award deriv | 2023-02-09 | 2023-02-13 | 110,000 | — | $0 | 110,000 | SEC↗ |
| Altschuler Steven | Director | A Award deriv | 2023-02-09 | 2023-02-13 | 27,400 | — | $0 | 27,400 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | A Award | 2023-02-09 | 2023-02-13 | 30,000 | — | $0 | 93,319 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | A Award | 2023-02-09 | 2023-02-13 | 75,000 | — | $0 | 290,351 | SEC↗ |
| Mansbach Harry H | Chief Medical Officer | A Award | 2023-02-09 | 2023-02-13 | 30,000 | — | $0 | 96,798 | SEC↗ |
| Martins Ryan | Chief Financial Officer | A Award | 2023-02-09 | 2023-02-13 | 30,000 | — | $0 | 62,868 | SEC↗ |
| Martins Ryan | Chief Financial Officer | S Sale | 2023-02-08 | 2023-02-10 | 1,480 | $14.41 | $21.3K | 32,868 | SEC↗ |
| Le-Nguyen Quoc | See Remarks | F Tax w/h | 2023-02-05 | 2023-02-07 | 1,390 | $13.24 | $18.4K | 63,319 | SEC↗ |
| Martins Ryan | Chief Financial Officer | F Tax w/h | 2023-02-05 | 2023-02-07 | 592 | $13.24 | $7.8K | 34,348 | SEC↗ |
| PALEKAR ROHAN | Chief Executive Officer | F Tax w/h | 2023-02-05 | 2023-02-07 | 4,078 | $13.24 | $54.0K | 215,351 | SEC↗ |